Name

Biomarkers of Aging Consortium

Legal name

Biomarkers of Aging Consortium

Website

https://agingconsortium.org

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Aging Biomarker Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

akta.pro secondary industry

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Aging biomarker research
• Biomarker validation frameworks
• Open-source bioinformatics library
• Geroscience research consortium
• Biological age measurement

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Donations and Grants: The consortium is fiscally sponsored by Methuselah Foundation and accepts tax-deductible donations. Donations support research initiatives, data-sharing efforts, scientific collaborations, and infrastructure. Donors may allocate contributions to specific programs including Manuscript development, Biolearn, The Biomarkers of Aging Challenge, The Longevity Study, and yearly Conference.
2. Conference Revenue: Revenue from conference registration fees, with speaker travel reimbursements up to $500 domestic and $1,000 international.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

The Biomarkers of Aging Consortium is a nonprofit scientific consortium that develops, validates, and standardizes biomarkers of aging through open-science programs. Its core offerings include Biolearn (an open-source library for unified biomarker evaluation), an annual conference at Harvard Medical School, collaborative consensus manuscripts, a Challenge competition series, and The Longevity Study longitudinal research program. The consortium serves academic researchers, clinicians, longevity biotech companies, and regulatory bodies seeking standardized tools to measure aging and assess longevity interventions.

Product overview

The Biomarkers of Aging Consortium is an open science, collaborative research organization that offers a unified portfolio of programs for advancing geroscience. Its core offerings include Biolearn (an open-source Python library for standardized biomarker evaluation), an Annual Conference series, collaborative Manuscripts developing consensus roadmaps, the Biomarkers of Aging Challenge competition, and The Longevity Study longitudinal research program. These offerings work together to establish standardized, clinically validated ways to measure aging and assess intervention outcomes.

Differentiator

Problem solved

Functional benefit

Brands

• Biolearn: A first-of-its-kind, open source library designed for the evaluation and unified validation of biomarkers of aging, containing curated and harmonized large, high-quality omics and health datasets.
• Biomarkers of Aging Challenge Series
• The Longevity Study

Products and services

• Biolearn Open-source Python library designed for the evaluation and unified validation of biomarkers of aging, containing curated and harmonized large, high-quality omics and health datasets. It enables standardized evaluation across diverse cohorts with unified data processing pipelines, quality control, and cell-type deconvolution capabilities.
• Annual Biomarkers of Aging Conference A 2-day in-person annual conference at Harvard Medical School in Boston featuring cutting-edge academic science of biomarkers of aging along with translational, clinical, and regulatory aspects. Attracts world-leading academic and industry scientists.
• Community Roadmapping Manuscripts Collaborative manuscripts program bringing together leading researchers and stakeholders in the geroscience field to build and publish consensus roadmaps and standards for the systematic development and validation of biomarkers of aging. Published in Nature Medicine, Nature Aging, Cell, and Lancet Healthy Longevity.
• Biomarkers of Aging Challenge A challenge series stimulating innovation and collaboration in the development of next-generation biomarkers that are highly predictive of chronological age, mortality, and multi-morbidity. The series includes $200,000 in awards across a three-phase competition.
• The Longevity Study A longitudinal multi-modal deep-profiling study leveraging community-based cohorts and state-of-the-art molecular and functional profiling to explore how aging affects molecular and functional levels, shedding light on the changes driving functional decline.

Quantifiable outcome

• Horvath skin and blood clock achieved highest chronological age accuracy (R² = 0.88)
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

18 partnerships are on record, tiered core and minor.

• Stanford MedicinecoreStrategic or Co-development PartnerStanford School of Medicine is a key collaborating institution for The Longevity Study and hosts consortium leadership including Mahdi Moqri. Stanford investigators contribute to consortium programs including the Stanford 1000 Immunomes Project.
• King's College LondoncoreStrategic or Co-development PartnerKing's College London collaborates through Dr. Chiara Herzog's work on epigenetic and multi-omic biomarkers of aging and cancer. Dr. Herzog serves on the consortium's Executive Committee.
• Buck Institute for Research on AgingcoreStrategic or Co-development PartnerThe Buck Institute co-hosted the inaugural 2023 Symposium and contributes leadership including Dr. David Furman (Associate Professor, Director of AI and Bioinformatics Core) and Dr. Eric Verdin (President and CEO).
• National University of Singapore (NUS) MedicinecoreStrategic or Co-development PartnerNUS Medicine collaborates through Dr. Andrea Maier (Oon Chiew Seng Professor in Medicine, Co-Director of Center for Healthy Longevity) and contributes to consortium research on healthy aging biomarkers.
• Columbia Aging CentercoreStrategic or Co-development PartnerColumbia University contributes leadership including Dr. Daniel Belsky (Associate Professor, Robert N Butler Columbia Aging Center) who developed the DunedinPACE epigenetic clock.
• UCSFcoreStrategic or Co-development PartnerUniversity of California San Francisco collaborates through Dr. Eric Verdin and contributes to consortium programs including biomarker research and validation efforts.
• Altos LabscoreStrategic or Co-development PartnerAltos Labs contributes leadership including Dr. Steve Horvath (Principal Investigator, renowned for developing epigenetic clocks) and collaborates on biomarker development and validation research.
• XPRIZE FoundationcoreStrategic or Co-development PartnerXPRIZE Healthspan is a key strategic partner, with Dr. Jamie Justice (Executive VP Health Domain, Director of $101M Healthspan Prize) serving on the Scientific Advisory Board. The consortium partners with XPRIZE on the Biomarkers of Aging Challenge.
• Foresight InstitutecoreGTM or Marketing PartnerForesight Institute collaborates on consortium webinars, updates, and community building. Allison Duettmann (President and CEO) serves on the consortium's Executive Committee.
• VitaDAOminorStrategic or Co-development PartnerVitaDAO longevity-focused DAO collaborated on podcast content featuring consortium leadership discussing biomarkers and longevity research.
• BioAge LabsminorStrategic or Co-development PartnerBioAge Labs contributes leadership including Dr. Kristen Fortney (CEO & co-founder) and Dr. Eric Morgen, who serves as speakers at consortium conferences.
• OpenCuresminorStrategic or Co-development PartnerOpenCures provides conference sponsorship and supports open science initiatives in the longevity research community.
• Broad InstituteminorStrategic or Co-development PartnerBroad Institute contributes speakers including Dr. Fei Chen and is a conference sponsor for consortium events.
• Inside TrackerminorStrategic or Co-development PartnerInside Tracker (founded by Dr. Gil Blander) contributes as a conference sponsor and Dr. Blander serves as a speaker at consortium events.
• Retro BiosciencesminorStrategic or Co-development PartnerRetro Biosciences (led by Dr. Joe Betts-LaCroix) contributes as a conference sponsor and Dr. Betts-LaCroix serves as a speaker.
• Regenerative BiominorStrategic or Co-development PartnerRegenerative Bio (Regen Bio) contributes as a conference sponsor and Dr. Gavin Zhou serves as a speaker at consortium events.
• Insilico MedicineminorStrategic or Co-development PartnerInsilico Medicine contributes through Dr. Alex Zhavoronkov's involvement as a speaker at consortium conferences.
• Longevity.technologyminorGTM or Marketing PartnerLongevity.technology is a media partner for consortium conferences and provides coverage of consortium activities.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Hevolution Foundation: Major longevity-focused philanthropic foundation providing conference sponsorship and grants for aging research globally; operates at larger scale across the same geroscience funding ecosystem.
• Altos Labs: Well-capitalized cellular rejuvenation biotech employing Steve Horvath; a strategic partner whose proprietary biomarker work and clinical translation agenda both complement and potentially outpace the consortium's open frameworks.
• Methuselah Foundation: Fiscal sponsor of the Biomarkers of Aging Consortium and the most direct operational peer; Methuselah Foundation funds longevity research, biotech startups, and prizes, sharing mission, leadership overlap (Dane Gobel), and donor base with the consortium.

Emerging players

• BioAge Labs: Clinical-stage biotech identifying drug targets through aging biology; CEO Kristen Fortney is a consortium speaker and BioAge is a Minor-tier partner, making it a directly comparable industry counterpart pursuing aging biomarker translation.
• VitaDAO: Decentralized autonomous organization funding longevity research; partnered on consortium podcast content and shares the open-science, community-funded approach to advancing geroscience.
• Insilico Medicine: AI-driven longevity biotech that contributes speakers and engages in aging biomarker validation; comparable translational focus on aging biomarkers and intervention endpoints though pursued commercially.

Direct peers

• Foresight Institute: Long-term-oriented technology nonprofit that co-hosts webinars and Biomarkers of Aging Challenge updates; overlapping leadership (Allison Duettmann) and shared mission of advancing biotech for longevity.
• XPRIZE Healthspan: $101M XPRIZE Healthspan prize operates in the same longevity/biomarker translational space and is an active strategic partner (Dr. Jamie Justice on SAB); comparable use of large prize-based incentive structures to drive aging research.
• Buck Institute for Research on Aging: Core academic partner that hosted the inaugural symposium and shares leadership (Eric Verdin, David Furman); operates one of the leading geroscience research centers producing biomarker and aging-clock research the consortium benchmarks.
• American Federation for Aging Research (AFAR): Long-standing nonprofit funding biomedical aging research and a partner of the consortium; AFAR's mission of advancing geroscience through grants, training, and convening overlaps directly with the consortium's consensus-building role.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/playlist?list=PLJuk_VePAqbXQluW5QOt9dnkavP4MYDBN
• Xx.com/agingbiomarkers
• LinkedInlinkedin.com/company/biomarkers-of-aging-consortium

Revenue estimate

Valuation estimate

Number of profiles

Profiles26 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomarkers of Aging Consortium